Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Hematologic Neoplasms 1

Interventions

Cyclophosphamide 14fludarabine 10fludarabine phosphate 8Whole-Body Irradiation 7thymoglobulin 5Thiotepa 5Tacrolimus 5Stem Cell Transplantation 5Standard of Care 5Practice Guidelines as Topic 5Nivolumab 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Azacitidine 5venetoclax 4Radiotherapy 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 4Rituximab 3Mesna 3Leucovorin 3Dexamethasone 3Calcium Dobesilate 3Alemtuzumab 3ruxolitinib 2ceritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Neoplasms × Aftercare × Clear all
NCT03943082 2021-11-16

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

University of California, San Francisco

Phase NA Terminated
252 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡